Christopher Leamon - Fusion Pharmaceuticals Chief Officer
| FUSNDelisted Stock | USD 3.75 0.33 8.09% |
Insider
Christopher Leamon is Chief Officer of Fusion Pharmaceuticals
| Age | 58 |
| Phone | 289 799 0891 |
| Web | https://www.fusionpharma.com |
Christopher Leamon Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christopher Leamon against Fusion Pharmaceuticals stock is an integral part of due diligence when investing in Fusion Pharmaceuticals. Christopher Leamon insider activity provides valuable insight into whether Fusion Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Fusion Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Fusion Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christopher Leamon over six months ago Acquisition by Christopher Leamon of 106100 shares of Fusion PharmaceuticalsI at 8.44 subject to Rule 16b-3 |
Fusion Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2334) % which means that it has lost $0.2334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4711) %, meaning that it created substantial loss on money invested by shareholders. Fusion Pharmaceuticals' management efficiency ratios could be used to measure how well Fusion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Fusion Pharmaceuticals currently holds 50.33 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Fusion Pharmaceuticals has a current ratio of 17.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Fusion Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Ian Critchley | Spero Therapeutics | N/A | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| John Moriarty | Olema Pharmaceuticals | 56 | |
| Alexander MS | Fennec Pharmaceuticals | N/A | |
| Gwen Carscadden | RAPT Therapeutics | 63 | |
| MBA MD | Spero Therapeutics | 43 | |
| Gillian Langford | Bicycle Therapeutics | N/A | |
| Mark Meier | Fennec Pharmaceuticals | N/A | |
| Luis Sanay | Harmony Biosciences Holdings | N/A | |
| Richard Waldron | Bioatla | 70 | |
| MBA CFA | Bolt Biotherapeutics | 60 | |
| Keith MBA | Keros Therapeutics | 54 | |
| Eric MD | Bioatla | 60 | |
| Simon MBBS | Keros Therapeutics | 54 | |
| James Brady | Spero Therapeutics | N/A | |
| David Myles | Olema Pharmaceuticals | 61 | |
| Lina Gugucheva | NewAmsterdam Pharma | 37 | |
| Jasbir Seehra | Keros Therapeutics | 68 | |
| MBA MD | Ikena Oncology | 59 | |
| Karen Bergman | Bolt Biotherapeutics | N/A | |
| PharmD Faltaos | Olema Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 |
Fusion Pharmaceuticals Leadership Team
Elected by the shareholders, the Fusion Pharmaceuticals' board of directors comprises two types of representatives: Fusion Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fusion. The board's role is to monitor Fusion Pharmaceuticals' management team and ensure that shareholders' interests are well served. Fusion Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fusion Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Leamon, Chief Officer | ||
| John Valliant, CEO Founder | ||
| Mohit Rawat, President Officer | ||
| Eric Hoffman, Senior Development | ||
| Dmitri MD, Chief Officer | ||
| Maria Stahl, Chief Officer | ||
| Victor Paulus, VP Affairs | ||
| Cara Ferreira, Chief Staff | ||
| Joanne Schindler, Executive Development | ||
| Eric Burak, Chief Officer | ||
| John CPA, Chief Officer | ||
| Amanda Cray, Senior Communications |
Fusion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fusion Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.47 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (54.04) % | |||
| Current Valuation | 1.69 B | |||
| Shares Outstanding | 85.06 M | |||
| Shares Owned By Insiders | 0.46 % | |||
| Shares Owned By Institutions | 86.80 % | |||
| Number Of Shares Shorted | 3.06 M | |||
| Price To Book | 8.13 X | |||
| Price To Sales | 874.50 X |
Pair Trading with Fusion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fusion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fusion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Fusion Stock
| 0.39 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
| 0.34 | PG | Procter Gamble Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Fusion Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fusion Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fusion Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fusion Pharmaceuticals to buy it.
The correlation of Fusion Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fusion Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fusion Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fusion Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Fusion Stock
If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |